Investment Thesis
Pureos Bioventures invests in biotech companies developing innovative therapeutics, with a focus on next-generation biological drugs and drug formats. They aim to impact patients’ lives by advancing treatments for severe diseases, particularly in oncology, fibrosis, rare neurological disorders, and inflammatory diseases.
Stage Focus
Preclinical to clinical-stage biotech companies
Preferred startup development maturity for initial funding deployment.
Sectors & Themes
Innovative therapeutics, next-generation biological drugs, antibody-drug conjugates (ADCs), gene therapies, and precision monoclonal antibodies
Core thematic spaces, technologies, and target market segments of interest.
Check Size Range
N/A
Standard financial allocation per investment round.
Outreach & Dossier Intelligence
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
Investment Team (28)
B
Ben Morgan
General Partner Board
D
Dominik Escher
Managing Partner
D
Dr. Anne Grahl
Investment Manager
D
Dr. Bruno Teta
Pureos Partners Board
D
Dr. Butrint Aliu
Analyst
D
Dr. Dominik Escher
Managing Partner
D
Dr. Dragan Grabulovski
Venture Partner
D
Dr. Klaus Breiner
Managing Partner
D
Dr. Lars Nieba
Venture Partner
D
Dr. Martin Münchbach
Managing Partner
D
Dr. Mathieu Simon
Advisory Board
D
Dr. Matthias Staehelin
Pureos Partners Board
D
Dr. Omar Khwaja
Advisory Board
D
Dr. Omar Khwaja, MD PhD
Advisory Board
D
Dr. Roberto Iacone
Venture Partner
D
Dr. Sonia Quaratino
Advisory Board Member
D
Dr. Sonia Quaratino, MD PhD
Advisory Board
D
Dr. Veronica Gambillara Fonck
Partner
D
Dr. Ximing Ding
Principal
I
Ian Metcalfe
Venture Partner
K
Karen Haith
General Partner Board
M
Martin Münchbach
Managing Partner and Founding Partner
P
Pascal Mahieux
General Partner Board
P
Prof. Dr. Bernd Seizinger
Advisory Board
P
Prof. Dr. Roger Nitsch
Advisory Board
P
Prof. Dr. Sai Reddy
Venture Partner
P
Prof. Dr. Thomas Baumert
Advisory Board Member
S
Stefano Lamaro
Analyst